Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By
integrating the strengths of these two companies, including our approximately 37,000 colleagues globally, we aim to
deliver increased access to affordable, quality medicines for patients worldwide.
Our global portfolio includes best-in-class, iconic brand name products as well as global key brands; generics,
including branded and complex generics; biosimilars; and over-the-counter offerings across a wide range of
therapeutic areas. We are committed to helping create healthier communities worldwide through education,
outreach and better access to treatment.
At Viatris, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach
across North America, Europe, the Asia Pacific region and emerging markets. Our high quality global manufacturing,
scientific excellence and vast supply chain network mean we are uniquely positioned to improve access to medicine
for patients worldwide.